Sign inCreate account

Report workspace tools

NCT05350423COMPLETEDanonymous

Use of Urinary Biomarkers to Quantify Degree of Renal, Parenchymal and Urothelial Damage During Ureteroscopy

Sponsor

Source record

Icahn School of Medicine at Mount Sinai

Phase

Source record

NA

Modality

AI-normalized

medical device

Target

AI-normalized

Thulium Fibre Laser, Holmium:Yttrium-Aluminum-Garnet

Indication / condition

AI-normalized

Nephrolithiasis

Intervention

Source record

Thulium Fibre Laser, Holmium:Yttrium-Aluminum-Garnet

Source & freshness

Source record

NCT ID

NCT05350423

Original source

ClinicalTrials.gov

Source last updated

Dec 07, 2023

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT05350423

Title

Use of Urinary Biomarkers to Quantify Degree of Renal, Parenchymal and Urothelial Damage During Ureteroscopy

Sponsor

Icahn School of Medicine at Mount Sinai

Status

COMPLETED

Phase

NA

Condition raw

Nephrolithiasis

Condition normalized

Nephrolithiasis

Modality raw

medical device

Modality normalized

medical device

Target raw

Thulium Fibre Laser, Holmium:Yttrium-Aluminum-Garnet

Target normalized

Thulium Fibre Laser, Holmium:Yttrium-Aluminum-Garnet

Interventions

Thulium Fibre Laser, Holmium:Yttrium-Aluminum-Garnet

Public preview

Source record

This is an ongoing randomized controlled trial of patients undergoing URSLL with unilateral non-obstructing renal stones. Patients are randomized to undergo URSLL with either the TFL or Ho:YAG laser. Each patient's urine is collected immediately pre-op (V1), 1 hour post-op (V2), and 10 days post-op (POD#10, V3). Samples are analyzed by enzyme-linked immunosorbent assay (ELISA) for the following biomarkers: Kidney injury molecule-1 (KIM-1), Neutrophil gelatinase-associated lipocalin (NGAL), and β2-microglobulin (β2M), then normalized to urine creatinine.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Use of Urinary Biomarkers to Quantify Degree of Renal, Parenchymal and Urothelial Damage During Ureteroscopy

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT05350423

Status

COMPLETED

Phase

NA

Sponsor

Icahn School of Medicine at Mount Sinai

Executive brief

Investment-Ready Snapshot

This is an ongoing randomized controlled trial of patients undergoing URSLL with unilateral non-obstructing renal stones. Patients are randomized to undergo URSLL with either the TFL or Ho:YAG laser. Each patient's urine is collected immediately pre-op (V1), 1 hour post-op (V2), and 10 days post-op (POD#10, V3). Samples are analyzed by enzyme-linked immunosorbent assay (ELISA) for the following biomarkers: Kidney injury molecule-1 (KIM-1), Neutrophil gelatinase-associated lipocalin (NGAL), and β2-microglobulin (β2M), then normalized to urine creatinine.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedDec 07, 2023
Internal syncJun 11, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT05350423

Indication

Nephrolithiasis

Modality

medical device

Target

Thulium Fibre Laser, Holmium:Yttrium-Aluminum-Garnet

Intervention

Thulium Fibre Laser, Holmium:Yttrium-Aluminum-Garnet

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.